Home/Filings/4/0001213900-21-020632
4//SEC Filing

Uknis Marc 4

Accession 0001213900-21-020632

CIK 0001816736other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 4:06 PM ET

Size

5.6 KB

Accession

0001213900-21-020632

Insider Transaction Report

Form 4
Period: 2021-02-05
Uknis Marc
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-02-05+277,117277,117 total
    Exercise: $12.66Exp: 2031-02-04Common Stock (277,117 underlying)
Footnotes (1)
  • [F1]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

Documents

1 file

Issuer

Gemini Therapeutics, Inc. /DE

CIK 0001816736

Entity typeother

Related Parties

1
  • filerCIK 0001843161

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 4:06 PM ET
Size
5.6 KB